Posted by Michael Wonder on 08 Aug 2019
Decision for funding in the immunosuppressant, oncology, vasodilator and smoking cessation therapeutic areas
8 August 2019 - PHARMAC is pleased to announce the approval of a decision relating to medicines in the immunosuppressant, oncology, vasodilator and smoking cessation areas.
In summary, this will result in the following changes from 1 September 2019:
- Adalimumab (Humira) access will be widened to include treatment of severe or chronic ocular inflammation.
- Dexrazoxane will be funded in DHB hospitals for cardioprotection in children and young adults treated with anthracycline chemotherapy.
- Sildenafil access will be widened to include people who have erectile dysfunction as a result of spinal cord injury.
